Collapsed engineering firm Forge Group has defeated an appeal seeking to block its liquidators from bringing a case against engineering company Clough Limited for alleged insider trading during the 2013 sale of a $187 million stake in the company.
From the ongoing saga of the high-profile Christian Porter action against the ABC to “backyard” litigation testing the serious harm bar, defamation cases made headlines in 2022, with winners and losers alike shelling out millions to lawyers to protect their reputations.
Two former staffers of senator Jacqui Lambie who represented themselves in an unsuccessful unfair dismissal case have been hit with nearly $50,000 in legal costs each due to their “unreasonable conduct” in the case, including attempts to turn the proceeding into “a trial by media.”
Mining company Downer EDI has won its bid to review documents between Alinta Energy and a superintendent who allegedly acted improperly in a spat over a $208 million solar gas hybrid project in the Pilbara region.
The University of Sydney has appealed a judgment finding it unlawfully terminated a political economy lecturer for showing students a slide of a Nazi swastika superimposed on the Israeli flag.
The founder of investment group Mayfair 101 must foot half his costs of a successful appeal of a 20-year ban on fund raising because of the many “spurious” grounds of appeal he pressed.
Ashurst has lured a partner from Hall & Wilcox as the firm looks to expand its Sydney real estate team.
The maker of Vagisil personal care products has filed a trade mark suit against pharmaceuticals and cosmetic company Dr Wolff over its new line of Vagisan products, arguing the name is likely to confuse consumers.
Despite recent class actions against Medibank and Optus for cybersecurity breaches, class actions over cyber attacks will not become common because they involve “a lot of work for not a lot of money”, a lawyer has predicted.
A judge has hit Alkaloids of Australia with a nearly $2 million penalty for engaging in cartel conduct and sentenced its former export manager to a term of imprisonment for his involvement in fixing prices for a key chemical in anti-spasmodic drug Buscopan.